|

EGFR-TKI inhibitor based on investigator's choice Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 3: 1

Top Sponsors

  • ArriVent BioPharma, Inc.1

Indications

  • EGFR Uncommon Mutations1
  • EGFR PACC1
  • EGFR P-Loop and Alpha C-Helix Compressing1
  • Advanced Non-Small Cell Lung Cancer1
  • Metastatic Non-Small Cell Lung Cancer1

Los Angeles, California1 trial

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

USC/Norris Comprehensive Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.